ROS1 and metastatic neoplasm: In pivotal clinical trials involving adult patients with treatment-naïve locally advanced or metastatic disease, entrectinib demonstrated significant therapeutic efficacy across ROS1-positive NSCLC and NTRK fusion-positive solid tumors—regardless of baseline central nervous system (CNS) metastasis status (8).